Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

We previously reported that the administration of bevacizumab for pancreatic neuroendocrine tumors inhibited angiogenesis in the host, resulting in tumor growth inhibition. In light of these results, we compared the effect of bevacizumab/gemcitabine/S-1 combination therapy vs. bevacizumab monotherap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: KASUYA, KAZUHIKO, NAGAKAWA, YUICHI, SUZUKI, MINAKO, SUZUKI, YOSHIAKI, KYO, BUNSO, SUZUKI, SATORU, MATSUDO, TAKAAKI, ITOI, TAKAO, TSUCHIDA, AKIHIKO, AOKI, TATSUYA
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2012
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3438701/
https://ncbi.nlm.nih.gov/pubmed/22969935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2012.456
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados